vs
Side-by-side financial comparison of KKR Real Estate Finance Trust Inc. (KREF) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
KKR Real Estate Finance Trust Inc. is the larger business by last-quarter revenue ($25.8M vs $18.6M, roughly 1.4× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs -101.7%, a 167.5% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -26.6%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -18.8%).
KKR Real Estate Finance Trust Inc. is a specialized real estate finance firm sponsored by global investment firm KKR. It primarily originates, acquires, and manages a portfolio of senior secured commercial real estate loans, mostly backed by high-quality institutional commercial properties across the United States, delivering stable risk-adjusted returns to investors via interest income from its diversified assets.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
KREF vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.8M | $18.6M |
| Net Profit | $-26.2M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | -105.1% | 56.3% |
| Net Margin | -101.7% | 65.7% |
| Revenue YoY | -26.6% | 1808.5% |
| Net Profit YoY | -229.6% | 376.5% |
| EPS (diluted) | $-0.49 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.8M | $18.6M | ||
| Q3 25 | $25.3M | $334.0K | ||
| Q2 25 | $30.2M | $1.4M | ||
| Q1 25 | $31.3M | $257.0K | ||
| Q4 24 | $35.1M | $977.0K | ||
| Q3 24 | $37.0M | $660.0K | ||
| Q2 24 | $40.4M | $736.0K | ||
| Q1 24 | $39.1M | $1.4M |
| Q4 25 | $-26.2M | $12.3M | ||
| Q3 25 | $13.8M | $-8.6M | ||
| Q2 25 | $-29.7M | $-6.9M | ||
| Q1 25 | $-4.9M | $-5.4M | ||
| Q4 24 | $20.3M | — | ||
| Q3 24 | $-7.4M | $-2.8M | ||
| Q2 24 | $25.8M | $-14.5M | ||
| Q1 24 | $-3.1M | $411.0K |
| Q4 25 | -105.1% | 56.3% | ||
| Q3 25 | 50.4% | -2516.5% | ||
| Q2 25 | -101.3% | -701.0% | ||
| Q1 25 | -18.3% | -3350.2% | ||
| Q4 24 | 55.8% | — | ||
| Q3 24 | -19.6% | -1563.6% | ||
| Q2 24 | 63.3% | -1255.0% | ||
| Q1 24 | -8.7% | -692.5% |
| Q4 25 | -101.7% | 65.7% | ||
| Q3 25 | 54.4% | -2572.2% | ||
| Q2 25 | -98.5% | -504.8% | ||
| Q1 25 | -15.5% | -2097.7% | ||
| Q4 24 | 57.7% | — | ||
| Q3 24 | -20.0% | -425.5% | ||
| Q2 24 | 63.9% | -1964.4% | ||
| Q1 24 | -7.9% | 29.9% |
| Q4 25 | $-0.49 | $0.25 | ||
| Q3 25 | $0.12 | $-0.17 | ||
| Q2 25 | $-0.53 | $-0.14 | ||
| Q1 25 | $-0.15 | $-0.11 | ||
| Q4 24 | $0.22 | — | ||
| Q3 24 | $-0.19 | $-0.06 | ||
| Q2 24 | $0.29 | $-0.30 | ||
| Q1 24 | $-0.13 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $84.6M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $49.4M |
| Total Assets | $6.5B | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $84.6M | $40.0M | ||
| Q3 25 | $204.1M | $37.9M | ||
| Q2 25 | $107.7M | $44.8M | ||
| Q1 25 | $106.4M | $40.6M | ||
| Q4 24 | $104.9M | $59.3M | ||
| Q3 24 | $108.8M | $68.8M | ||
| Q2 24 | $107.2M | $73.0M | ||
| Q1 24 | $106.5M | $80.2M |
| Q4 25 | $1.2B | $49.4M | ||
| Q3 25 | $1.2B | $36.4M | ||
| Q2 25 | $1.2B | $44.5M | ||
| Q1 25 | $1.3B | $50.5M | ||
| Q4 24 | $1.3B | $55.1M | ||
| Q3 24 | $1.4B | $58.5M | ||
| Q2 24 | $1.4B | $60.4M | ||
| Q1 24 | $1.4B | $74.1M |
| Q4 25 | $6.5B | $59.0M | ||
| Q3 25 | $6.5B | $51.1M | ||
| Q2 25 | $6.8B | $60.7M | ||
| Q1 25 | $6.6B | $67.9M | ||
| Q4 24 | $6.4B | $90.6M | ||
| Q3 24 | $6.8B | $99.0M | ||
| Q2 24 | $7.1B | $107.8M | ||
| Q1 24 | $7.3B | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $72.3M | $18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $72.3M | $18.4M | ||
| Q3 25 | $18.5M | $-8.7M | ||
| Q2 25 | $21.1M | $-7.5M | ||
| Q1 25 | $15.9M | $-7.5M | ||
| Q4 24 | $132.6M | $-24.0M | ||
| Q3 24 | $49.1M | $765.0K | ||
| Q2 24 | $30.6M | $-10.9M | ||
| Q1 24 | $34.5M | $-4.0M |
| Q4 25 | — | 1.50× | ||
| Q3 25 | 1.34× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.54× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.19× | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KREF
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
